Ongoing research on myo inositol supplements continues to show that it may be effective as an agent for losing weight, controlling appetite by lowering leptin levels, and maintaining strong hair growth.
Myo inositol also has been shown to have positive effects on female reproductive matters in women with polycystic ovary syndrome (PCOS) such as improving ovarian functioning, enhancing egg quality, accommodating healthy follicular development, and increasing the chances of conception.
Myo inositol is the most common form of inositol, a vitamin-like carbohydrate that is integral to all animal life forms. Myo inositol is synthesized via phosphorylated glucose and is utilized as a go-to secondary messenger for delivering nerve impulses throughout the body and brain.
Taking Myo-inositol supplements may improve mood balance, improve insulin resistance in women with PCOS, and support cellular health and integrity.
While the body is capable of producing inositol in the kidneys (up to 2 g per day), studies have found dosages of up to 18 grams effective for different health needs when the body may be deficient. Increasing intake can be accommodated through choosing myo-inositol rich foods or by taking supplements in powder or capsule form.



- Supports brain & liver health
- Involved in mood regulation & nerve signalling
- Improves insulin sensitivity for PCOS, fertility & weight loss
The Need for Myo Inositol Supplements
Related Topics
Scientifically known as cyclohexane-1,2,3,4,5,6-hexol, inositol is a common natural carbohydrate that demonstrates vitamin-like traits.
It was previously classified in the B-Vitamin family as Vitamin B8, although it is not an essential substance in the diet, which is the requirement for being considered a vitamin.
The body synthesizes a few grams or less of inositol daily via glucose, primarily in the kidneys.
Myo inositol is manufactured, mainly in the kidneys, in two basic steps. Glucose-6-phosphate (G-6-P) is required to initiate the process.
In the first step, G-6-P is isomerised to myo-inositol 1-phosphate via ISYNA1, a synthase protein enzyme of inositol triphosphate. Next, the myo-inositol 1-phosphate is dephosphorylated by IMPase (inositol monophosphatase). This results in free form myo inositol.
Inositol is a 6-fold cyclohexane polyol (alcohol sugar). It can exist as one of nine derived stereoisomers, which are compounds that have the same molecular makeup and differ solely via their atomic spatial arrangements.
Taste-wise, the sugar carbohydrate inositol is comparable to sucrose, only it is about half as sweet. Its highest dietary concentrations are found in organ meats, like livers, hearts, and brains.
More desirable options include fruits, especially bananas and melons, beans, legumes, green leafy vegetables, nuts, seeds, high bran cereals, and whole grains. Because inositol and its phosphorylated derivatives are so readily available in nature, deficiencies are rare.
However, levels may still become depleted or diminished by the following factors:
- Drinking too much coffee and/or alcohol
- Taking certain pharmaceutical drugs, especially sulfa antibiotic drugs or lithium
- Smoking tobacco products
- Excessive chronic stress
Benefits of Myo-Inositol Supplements
Myo inositol is one of those nine stereoisomers of inositol. It is the one that is most prevalent in nature. It acts to perform a wide range of mental and physical roles in the brain and body.
When you take a myo inositol supplement, you increase the bioavailable amount in your system. This may help to accommodate some of the following psychological and physiological functions.
Myo inositol molecules serve as the structural basis for a variety of secondary neurotransmission messengers. All major neurotransmitters including Dopamine and Serotonin utilize inositol, myo inositol, and other stereoisomers to relay their cellular messages.
Primary neurotransmitters cannot travel intracellularly and thus use secondary messengers derived from inositol to deliver these messages into the cellular nuclei. Because of this, myo-inositol and related compounds are currently being researched as natural remedies for depression and a variety of other mood disorders and mental conditions.
In eukaryotic cells, inositol and its phosphates regulate cell apoptosis, migration, and more. Additionally, inositol along with choline is a primary constituent of the phospholipid bilayer that envelops all eukaryotic cells. The group of lipids that accommodate cell structure integrity are called phosphatidylinositol phosphate lipids, less complexly known as PIP lipids.
Other functions of myo-inositol include transducing insulin signals, regulating intracellular Ca2+ levels, emulsifying fats and potentially promoting weight loss, maintaining cellular membrane potential, guiding nerve signals, and expressing genetic traits. Throughout the body, myo inositol and other forms of inositol act to perform a vast array of roles that are imperative to sustaining life.
Myo Inositol Pills for PCOS
Clinical research has concluded that there is a link between the development of PCOS and myo inositol. Polycystic ovary syndrome (PCOS) is also known as Stein-Leventhal Syndrome and/or hyperandrogenic anovulation (HA).
Among women, PCOS is one of the most prevalent disorders of the endocrine system. It is largely thought to be a disease of genetic influence, but the exact causes remain unknown. Insulin insensitivity causes elevated levels of insulin in the body, which in turn causes the ovaries to produce too much testosterone. Normal hormonal balances can become disrupted, leading to enlarged ovaries full of follicular cysts.
In research studies, taking a myo-inositol supplement along with a D-Chiro Inositol supplement in a 40:1 ratio has been found to alleviate many of the symptoms of this condition and improve the function of female reproductive systems. Using an inositol supplement has been seen to increase insulin sensitivity, decrease triglyceride and testosterone levels, improve androgenic effects, decrease blood pressure, and induce ovulation in trials on PCOS women.
The Natural Medicines database has rated Inositol as Possibly Effective for improving lithium-induced side effects, OCD, panic disorder, polycystic ovary syndrome (PCOS), and respiratory distress syndrome in premature babies. While research has been promising, more large-scale double-blind placebo-controlled studies are still needed to fully determine the effects supplemental inositol may have in the body.
At this time, Inositol is available as a dietary supplement only, and the FDA has not approved Inositol as a drug to prevent or treat any conditions.
Are Myo Inositol Supplements Safe?
For those considering buying a myo inositol supplement, it is always best to consult with a licensed doctor or nutritionist first. In the rare cases where side effects have been reported concerning taking a myo-inositol supplement, they have been quite mild, including headaches, dizziness, nausea, and upset stomach.
Although all forms of inositol have been repeatedly shown to be safe as supplements, there are some instances where supplementation may not be advisable. Pregnant and/or nursing women should not use any supplements without their doctor’s approval. Those who will be having any upcoming surgical procedures performed should discontinue taking myo inositol supplements at least a couple weeks before.
- Schneider S. Inositol transport proteins. FEBS Lett. 2015
- Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014
- Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014
- Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, Prati A, Simoncini T. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014
- Malvasi A, Casciaro F, Minervini MM, Kosmas I, Mynbaev OA, Pacella E, Monti Condesnitt V, Creanza A, Di Renzo GC, Tinelli A. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014
- Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014
- Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014
- Brusco GF, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci. 2013
- Dessì A, Fanos V. Myoinositol: a new marker of intrauterine growth restriction? J Obstet Gynaecol. 2013
- Phelps DL, Ward RM, Williams RL, Watterberg KL, Laptook AR, Wrage LA, Nolen TL, Fennell TR, Ehrenkranz RA, Poindexter BB, Michael Cotten C, Hallman MK, Frantz ID 3rd, Faix RG, Zaterka-Baxter KM, Das A, Bethany Ball M, Michael O'Shea T, Backstrom Lacy C, Walsh MC, Shankaran S, Sánchez PJ, et al. Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. Pediatr Res. 2013
- Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M, D'Aiuto M, Frasci G, Botti G, Grimaldi M, Cavalcanti E, Esposito G, Fucito A, Brillante G, D'Aiuto G, Ciliberto G. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials. 2013
- Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013
- Wilson MS, Livermore TM, Saiardi A. Inositol pyrophosphates: between signalling and metabolism. Biochem J. 2013
- Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013
- D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013
- Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013
- Matarrelli B, Vitacolonna E, D'Angelo M, Pavone G, Mattei PA, Liberati M, Celentano C. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013
- Wundenberg T, Mayr GW. Synthesis and biological actions of diphosphoinositol phosphates (inositol pyrophosphates), regulators of cell homeostasis. Biol Chem. 2012
- Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012
- López-González AA, Grases F, Monroy N, Marà B, Vicente-Herrero MT, Tur F, Perelló J. Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women. Eur J Nutr. 2013
- Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012
- Carlomagno G, De Grazia S, Unfer V, Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012
- Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012
- Santamaria A, Giordano D, Corrado F, Pintaudi B, Interdonato ML, Vieste GD, Benedetto AD, D'Anna R. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. 2012
- Gianfranco C, Vittorio U, Silvia B, Francesco D. Myo-inositol in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2011
- Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011
- Carlomagno G, Nordio M, Chiu TT, Unfer V. Contribution of myo-inositol and melatonin to human reproduction. Eur J Obstet Gynecol Reprod Biol. 2011
- Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011
- Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011
- Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. 2011
- Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol. 2011
- Berry GT. Is prenatal myo-inositol deficiency a mechanism of CNS injury in galactosemia? J Inherit Metab Dis. 2011
- Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A, D'Anna R. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011
- Bloch PJ, Weller AE, Doyle GA, Ferraro TN, Berrettini WH, Hodge R, Lohoff FW. Association analysis between polymorphisms in the myo-inositol monophosphatase 2 (IMPA2) gene and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010
- Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010
- Zheng H, Zhang L, Li L, Liu P, Gao J, Liu X, Zou J, Zhang Y, Liu J, Zhang Z, Li Z, Men W. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010
- Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009
- Di Daniel E, Kew JN, Maycox PR. Investigation of the H(+)-myo-inositol transporter (HMIT) as a neuronal regulator of phosphoinositide signalling. Biochem Soc Trans. 2009
- Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009
- Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online. 2008
- Forester BP, Finn CT, Berlow YA, Wardrop M, Renshaw PF, Moore CM. Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. Bipolar Disord. 2008
- Maeba R, Hara H, Ishikawa H, Hayashi S, Yoshimura N, Kusano J, Takeoka Y, Yasuda D, Okazaki T, Kinoshita M, Teramoto T. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J Nutr Sci Vitaminol (Tokyo). 2008
- McGrath BM, McKay R, Dave S, Seres P, Weljie AM, Slupsky CM, Hanstock CC, Greenshaw AJ, Silverstone PH. Acute dextro-amphetamine administration does not alter brain myo-inositol levels in humans and animals: MRS investigations at 3 and 18.8 T. Neurosci Res. 2008
- Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009
- Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008
- Michell RH. Inositol derivatives: evolution and functions. Nat Rev Mol Cell Biol. 2008
- Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007
- Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007
- Geiger JH, Jin X. The structure and mechanism of myo-inositol-1-phosphate synthase. Subcell Biochem. 2006
- Patel NC, DelBello MP, Cecil KM, Adler CM, Bryan HS, Stanford KE, Strakowski SM. Lithium treatment effects on Myo-inositol in adolescents with bipolar depression. Biol Psychiatry. 2006
- Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2006
- Kim H, McGrath BM, Silverstone PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol. 2005
- Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 2005
- Harwood AJ. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry. 2005
- Shawcross DL, Balata S, Olde Damink SW, Hayes PC, Wardlaw J, Marshall I, Deutz NE, Williams R, Jalan R. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol. 2004
- Elberling TV, Danielsen ER, Rasmussen AK, Feldt-Rasmussen U, Waldemar G, Thomsen C. Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves' disease. Neurology. 2003
- Agam G, Shamir A, Shaltiel G, Greenberg ML. Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord. 2002
- Nemets B, Talesnick B, Belmaker RH, Levine J. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. World J Biol Psychiatry. 2002
- Fisher SK, Novak JE, Agranoff BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem. 2002
- Harvey BH, Brink CB, Seedat S, Stein DJ. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002
- Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001
- Davanzo P, Thomas MA, Yue K, Oshiro T, Belin T, Strober M, McCracken J. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology. 2001
- Wilcox RA, Primrose WU, Nahorski SR, Challiss RA. New developments in the molecular pharmacology of the myo-inositol 1,4,5-trisphosphate receptor. Trends Pharmacol Sci. 1998
- Frey R, Metzler D, Fischer P, Heiden A, Scharfetter J, Moser E, Kasper S. Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res. 1998
- Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997
- Communi D, Vanweyenberg V, Erneux C. Molecular study and regulation of D-myo-inositol 1,4,5-trisphosphate 3-kinase. Cell Signal. 1995
- Shetty HU, Schapiro MB, Holloway HW, Rapoport SI. Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid. J Clin Invest. 1995
- Gani D, Downes CP, Batty I, Bramham J. Lithium and myo-inositol homeostasis. Biochim Biophys Acta. 1993
- Downes CP, Macphee CH. myo-inositol metabolites as cellular signals. Eur J Biochem. 1990
- Hanley MR, Jackson TR, Vallejo M, Patterson SI, Thastrup O, Lightman S, Rogers J, Henderson G, Pini A. Neural function: metabolism and actions of inositol metabolites in mammalian brain. Philos Trans R Soc Lond B Biol Sci. 1988
- Greene DA. Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve. Drugs. 1986
- Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr. 1986
- Clements RS Jr. Review of myo-inositol and sorbinil studies. Clin Physiol. 1985
- Popp-Snijders C, Lomecky-Janousek MZ, Schouten JA, van der Veen EA. myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment. Diabetologia. 1984
- Holub BJ. The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and disease. Adv Nutr Res. 1982
- Salway JG, Whitehead L, Finnegan JA, Karunanayaka A, Barnett D, Payne RB. Effect of myo-inositol on peripheral-nerve function in diabetes. Lancet. 1978
Article last updated on: May 12th, 2018 by Nootriment